RESEARCH ARTICLE

High Mannose-Binding Lectin Serum Levels Are Associated with Diabetic Retinopathy in Chinese Patients with Type 2 Diabetes

Qian Huang1, Guilian Shang2, Haohua Deng1, Jie Liu1, Yan Mei3, Yancheng Xu1*

1 Department of Endocrinology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei province, P. R. China, 2 Department of Rheumatology, Tianyou Hospital, Wuhan University of Science and Technology, Wuhan, Hubei province, P. R. China, 3 School of Stomatology, Wuhan University, Wuhan, Hubei province, P. R. China

* houzhaoely@163.com

Abstract

Objective
To investigate mannose-binding lectin (MBL) serum levels in type 2 diabetic patients with and without diabetic retinopathy (DR).

Methods
Serum MBL levels were determined in type 2 diabetic patients (N=324) as well as in 300 healthy control subjects. Multivariate analyses were performed using logistic regression models. Receiver operating characteristic curves (ROC) was used to test the overall predict accuracy of MBL and other markers.

Results
Diabetic patients with DR and vision-threatening diabetic retinopathy (VTDR) had significantly higher MBL levels on admission (P<0.0001 and P<0.0001). MBL improved the area under the receiver operating characteristic curve of the diabetes duration for DR from 0.82 (95% confidence interval [CI], 0.77–0.86) to 0.88 (95% CI, 0.82–0.96; P<0.01) and for VTDR from 0.85 (95% CI, 0.77–0.92) to 0.90 (95% CI, 0.83–0.96; P<0.01). Multivariate logistic regression analysis adjusted for common risk factors showed that serum MBL levels (per log-unit increase) was an independent predictor of DR (OR=3.45; 95%CI: 1.42–7.05) and VTDR (OR=4.42; 95%CI: 1.51–8.18).

Conclusion
MBL is a novel, independent diagnostic marker of DR in type 2 diabetic patients, suggesting that MBL may be involved in the pathogenesis of DR in diabetic patients.
Introduction

Type 2 diabetes (T2DM) has become a major public health problem in China. In 2009, the age-standardized prevalences of total diabetes and prediabetes were 9.7% and 15.5%, respectively, accounting for 92.4 million adults with diabetes and 148.2 million adults with prediabetes [1]. Diabetic retinopathy (DR) is the most frequent cause of new cases of blindness among adults aged 20–74 years[2]. Approximately 29% of U.S. adults with type 2 diabetes have DR [3]. Liu et al [4] reported that 14.8% Chinese patient with T2DM have DR.

The presence of DR was associated with an increased risk of all-cause mortality and cardiovascular events in diabetic patient [5]. Up to 21% of patients with T2DM have retinopathy at the time of first diagnosis of diabetes, and most develop some degree of retinopathy over time. Vision loss due to diabetic retinopathy results from several mechanisms and central vision may be impaired by macular edema or capillary nonperfusion[6]. Although the major risk factors for DR (e.g., hyperglycemia, hypertension, dyslipidemia) have been examined in many epidemiologic studies and clinical trials, there is considerable variation in the consistency, pattern, and strength of these risk factors [3].

Mannose-binding lectin (MBL) is synthesized by hepatocytes and belongs to the family of C-type lectins[7]. MBL is a part of the complement cascade and plays an important role in the first line of defense of the innate immune system against pathogenic microorganisms [8]. MBL exerts an important role in the innate immune system [9], and several studies have indicated that low levels of MBL affect the outcome of kidney graft survival [10], infectious diseases [11], critical illness [12] and neonatal sepsis and pneumonia [13]. Interestingly, high levels of MBL offer protection against invading microorganisms and may in other situations confer biological disadvantages [14]. MBL may aggravate local and systemic inflammation through complement activation and modulation of proinflammatory cytokine production [15]. Previous studies have suggested that increased MBL levels are associated with an increased risk of stroke and poor functional outcomes after stroke in Chinese population [16–17].

There have been great controversies in studying relationship between MBL and diabetic complications. Siezenga et al. [18] found that log MBL levels were not associated with the occurrence of cardiovascular events in type 2 diabetic South Asians, while Elawa et al [19] reported that elevated serum MBL in T2DM patients indicated a possible poor diabetic control and bad progression of the disease with possibility of the presence. Consistent with this, Bouwman et al. [20] concluded that MBL serum concentration and complex activity are increased in early-onset diabetic patients upon manifestation independently of genetic predisposition to high MBL production, indicating a possible role in the immunopathogenesis of type 1 diabetes. In addition, Hansen et al [21] found that the median MBL concentration was higher in type 1 diabetic patients than in healthy controls. However, no data are available on the role of MBL in the progression of DR in Chinese patients with T2DM. In this study, we therefore evaluated serum MBL levels in Chinese type 2 diabetic patients with and without diabetic retinopathy.

Method

We conducted a prospective cohort study at the endocrinology department of our hospital. We consecutively recruited 324 Chinese with type 2 diabetes aged 31–74 years between October 2012 and May 2014. Participants were excluded if they had a history of epilepsy or glaucoma, had undergone previous vitreal surgery, and/or had a cataract on examination. Participants who had no light perception or severe visual impairment in both eyes or had a severe infection in one or both eyes were excluded. A group of 300 age-matched healthy subjects served as control subjects. The study followed the tenets of the Declaration of Helsinki and was approved by
the Institute ethics committee of Zhongnan Hospital, Wuhan University, with written informed consent obtained from each participant.

We used the Canon CR6-45NM ophthalmic digital imaging system and Canon EOS 10D digital camera (Canon, Tokyo, Japan) to take 2 digital images per eye through a nonpharmacologicallydilated pupil. DR was defined as the presence of 1 or more retinal microaneurysms or retinal blot hemorrhages with or without more severe lesions (hard exudates, soft exudates, intraretinal microvascular abnormalities, venous beading, retinal new vessels, preretinal and vitreous hemorrhage, and fibroproliferans) using the Early Treatment Diabetic Retinopathy Study (ETDRS) grading standards[22]. DR severity was categorized as non-proliferative diabetic retinopathy (NPDR; level 20 through level 53) and proliferative diabetic retinopathy (PDR; level ≥60). Diabetic macular edema (DME) was defined as present or absent and classified as with or without clinically significant macular edema; and vision-threatening diabetic retinopathy (VTDR) was defined as the presence of PDR and/or DME. T2DM was defined as self-report of a previous diagnosis of the disease by a clinician (excluding gestational diabetes mellitus) or hemoglobin A1c (HbA1c) of 6.5% or greater [23]. At baseline, we requested individual participant data regarding presence and severity of DR, DME status, age, sex, ethnicity, diabetes type and duration, HbA1c, systolic and diastolic blood pressure, cigarette smoking status, BMI, and current use of diabetes, antihypertensive, and lipid-lowering medications.

Blood samples of patients and controls were obtained at 7:00 AM in the next morning of the day of inclusion under fasting state. 2 ml of blood were placed into a dry clean tube and left to clot at room temperature, and then separated by centrifugation for 15 min. Clotted blood was centrifuged within 1h and serum stored at -80°C. HbA1c was measured by high-performance liquid chromatography (HLC-723 G7; TOSHO, Japan) with a normal range of 4–6%. MBL was measured by time-resolved immune-fluorometric assay on serum samples. Microwells coated with anti-MBL antibody were incubated with dilutions of patient serum, were developed with europium-labelled anti-MBL antibody, and europium was quantified with time-resolved fluorometric assay (Baoman Biological Technology Co., Ltd, Shanghai, China). The detection limit was 1.8ug/L. The standard concentrations in these kits range from 1.8 to 100ug/L, providing a range of 180–10000ug/L at 1/100 dilution. The coefficients of variation (CV) for the intra- and inter-assay reproducibility are 4.0–5.8% and 6.7–9.4%, respectively.

Results are expressed as percentages for categorical variables and as medians (interquartile ranges, IQRs) for the continuous variables. Univariate data on demographic and clinical features were compared by Mann-Whitney U-test or Chi-Square test as appropriate. Correlations among continuous variables were assessed by the Spearman rank-correlation coefficient. To investigate whether MBL allows predicting of both DR and VTDR in diabetes different statistical methods were used. First, the relation of MBL with the two points was investigated with the use of logistic regression models. Therefore, common logarithmic transformation (ie, base 10) was performed to obtain normal distribution for skewed variables (ie, MBL concentrations) as the resulting model yielded smaller Akaike Information Criterion, which was chosen to compare the results. We used crude models and multivariate models adjusted for all significant predictors and report odds ratios (ORs). For multivariate analysis, we included confounders, known risk factors, and other predictors as assessed in univariate analysis. Second, receiver operating characteristic curves (ROC) was used to test the overall predict accuracy of MBL and other markers, and results were reported as area under the curve (AUC). All statistical analysis was performed with SPSS for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA)and the ROCR package (version 1.0–2), which is available from CRAN repository (http://cran.r-project.org/). Statistical significance was defined as P< 0.05.
Results

Patient Characteristics

There were 324 people with type 2 diabetes eligible for the study. The median age of patients included in this study was 55 (IQR, 42–68) years and 55.6% were men. The median time of diabetes duration was 7.5 (IQR, 6.0–10.0) years. DR was found in 115 patients (35.5%). Forty-one patients were defined as VTDR, thus the rate was 12.7%. Basal characteristics of those patients were provided in Table 1.

MBL and Clinical Varies

The results indicated that the serum MBL levels were significantly (P < 0.0001) higher in diabetes patients as compared to normal cases [2976 (IQR, 2421–3521 μg/L); 732 (IQR, 576–894 μg/L), respectively; Fig 1]. There was a modest positive correlation between levels of MBL and HbA1c (r = 0.385, P < 0.0001; Fig 2A). In addition, there was a significant, albeit weak, positive correlation between MBL levels and Hs-CRP (r = 0.159, P = 0.004; Fig 2B). Furthermore, there was no correlation between serum levels of MBL and other factors, such as, sex, age, creatinine, triglyceride, cholesterol, LDL and HDL, duration of diabetes, or daily insulin dose (P > 0.05).

MBL and DR

In the 115 patients with DR, serum MBL levels were higher compared with those in patients without DR [3388 (IQR, 2942–4080) μg/L vs. 2653 (IQR, 2157–3110) μg/L; P < 0.0001; Fig 3A]. In univariate logistic regression analysis, we calculated the odds ratio (OR) of log-transformed MBL levels as compared with other risk factors as presented in Table 2. With an unadjusted OR of 7.12 (95% CI, 3.81–13.15), MBL had a strong association with DR. After adjusting for all other significant predictors, MBL remained can be seen as an independent DR predictor with an adjusted OR of 3.45 (95% CI, 1.42–7.05; P < 0.0001). In multivariate analysis, there was an increased risk of DR associated with MBL levels ≥ 3521 μg/L (3rd quartiles; OR 3.10, 95% CI: 1.72–5.48; P < 0.0001) after adjusting for possible confounders. In addition, male sex, diabetes duration, HbA1c, Hs-CRP, intensive glucose treatment and systolic BP were also can be seen as DR predictors in multivariate analysis (Table 2). With an AUC of 0.84 (95% CI, 0.80–0.89), MBL showed a significantly greater discriminatory ability to diagnose DR as compared with Hs-CRP (AUC, 0.58; 95% CI, 0.52–0.65; P < 0.0001), HbA1c (AUC, 0.63; 95% CI, 0.56–0.70; P < 0.001) and age (AUC, 0.55; 95% CI, 0.49–0.63; P < 0.0001), while was in the range of diabetes duration (AUC, 0.82; 95% CI, 0.77–0.86; P = 0.056; Fig 4A). Interestingly, MBL improved the ability of diabetes duration to diagnose DR (AUC of the combined model, 0.88; 95% CI, 0.82–0.96; P < 0.01). This improvement was stable in an internal 5-fold cross validation that resulted in an average AUC (standard error) of 0.82 (0.030) for the diabetes duration and 0.88 (0.021) for the combined model, corresponding to a difference of 0.06 (0.009). Table 3.

MBL and VTDR

In the 41 patients with VTDR, serum MBL levels were higher compared with those in patients without DR [4087 (IQR, 3360–4290) μg/L vs. 2852 (IQR, 2234–3325) μg/L; P < 0.0001; Fig 3B]. In univariate logistic regression analysis, we calculated the odds ratio (OR) of log-transformed MBL levels as compared with other risk factors as presented in Table 2. In multivariate analysis, after adjusting for all other significant predictors, MBL remained can be seen as an independent DR predictor with an adjusted OR of 4.42 (95% CI, 1.51–8.18; P < 0.0001). In addition, there was an increased risk of DR associated with MBL levels ≥ 3521 μg/L (3rd quartiles; OR 7.89,
| Characteristics                        | Diabetes (N = 324) | Yes (N = 115) | No (N = 209) | P       |
|---------------------------------------|-------------------|--------------|-------------|---------|
| Age at baseline (IQR, years)          | 55(42–68)         | 56(42–68)    | 55(43–67)   | NS      |
| Male (%)                              | 55.6              | 52.2         | 57.4        | NS      |
| Diabetes duration (IQR, years)        | 7.5(6.0–10)       | 9.0(8.0–12.5)| 6.0(4.5–8.0)| <0.001  |
| BMI (IQR, kg/m2)                      | 29.1(26.5–31.4)   | 29.5(26.9–31.8) | 28.4(25.6–31.1) | NS      |
| Systolic blood pressure (IQR, mmHg)   | 134(127–144)      | 145(132–150) | 122(115–135)| <0.01   |
| Smoking status (%)                    | 40.1              | 39.1         | 40.7        | NS      |
| Current alcohol intake (%)            | 34.6              | 34.8         | 34.4        | NS      |
| Intensive glucose treatment (%)       | 41.7              | 47.8         | 38.3        | <0.01   |
| Blood pressure treatment (%)          | 37.7              | 38.3         | 37.3        | NS      |
| Use of lipid-lowering medication (%)  | 33.3              | 32.2         | 33.9        | NS      |
| Laboratory findings (IQR)             |                   |              |             |         |
| HbA1c (%)                             | 7.9(7.1–8.7)      | 8.5(7.6–9.7) | 7.2(6.4–8.1)| <0.001  |
| Serum creatinine (umol/L)             | 92(75–100)        | 94(77–103)   | 87(74–97)   | NS      |
| Total cholesterol (mmol/L)            | 4.7(3.9–5.5)      | 4.9(4.2–5.7) | 4.4(3.7–5.2)| <0.01   |
| Triglycerides (mmol/L)                | 1.5(0.9–1.8)      | 1.6(1.0–1.9) | 1.4(0.9–1.7)| NS      |
| LDL-cholesterol (mmol/l)              | 2.6(1.9–3.0)      | 2.6(2.1–3.1) | 2.5(1.9–2.9)| NS      |
| HDL-cholesterol (mmol/l)              | 1.5(1.3–1.7)      | 1.6(1.4–1.8) | 1.5(1.2–1.7)| NS      |
| Hs-CRP (mg/dL)                        | 0.98(0.44–2.10)   | 1.48(0.62–3.01)| 0.62(0.32–1.57)| <0.001  |
| MBL (ug/L)                            | 2976(2421–3521)   | 3388(2942–4080)| 2653(2157–3110) | <0.0001 |
| Any DR (%)                            | 35.5              | —            | —           |         |
| PDR                                   | 8.0               | —            | —           |         |
| DME                                   | 9.3               | —            | —           |         |
| VTDR                                  | 12.7              | —            | —           |         |

Results are expressed as percentages or as medians (IQR); BMI, body mass index; Hs-CRP, High-sensitivity- C-reactive protein; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy; DME, diabetic macular edema; VTDR; vision-threatening diabetic retinopathy.

doi:10.1371/journal.pone.0130665.t001

![Fig 1. A separate histogram of serum MBL levels in diabetic patients and normal controls.](image)
95% CI: 3.42–18.53; \( P < 0.0001 \) after adjusting for possible confounders. In addition, male sex, diabetes duration, HbA1c, Hs-CRP and systolic BP were also can be seen as DR predictors in multivariate analysis (Table 2).

With an AUC of 0.86 (95% CI, 0.80–0.92), MBL showed a significantly greater discriminatory ability to diagnose VTDR as compared with Hs-CRP (AUC, 0.61; 95% CI, 0.53–0.70; \( P < 0.0001 \)), HbA1c (AUC, 0.69; 95% CI, 0.60–0.78; \( P < 0.0001 \)) and age (AUC, 0.59; 95% CI, 0.53–0.64; \( P < 0.001 \)), while was in the range of diabetes duration (AUC, 0.85; 95% CI, 0.77–0.92; \( P = 0.126 \); Fig 4B). Again, MBL improved the ability of diabetes duration to diagnose VTDR (AUC of the combined model, 0.90; 95% CI, 0.83–0.96; \( P < 0.01 \)). This improvement

Fig 2. Correlation between the serum MBL levels and other factors (a) Correlation between the serum MBL levels and HbA1c; (b) Correlation between the serum MBL levels and Hs-CRP.

doi:10.1371/journal.pone.0130665.g002

Fig 3. Distribution of serum MBL levels in diabetic patients with different groups. The horizontal lines indicate mean levels. (A) Distribution of serum MBL levels in diabetic patients with DR and without DR; (B) Distribution of serum MBL levels in diabetic patients with vision-threatening diabetic retinopathy (VTDR) and without VTDR. P values refer to Mann-Whitney U tests for differences between groups.

doi:10.1371/journal.pone.0130665.g003
Table 2. Univariate and multivariate logistic regression analysis for DR and VTDR.

| Predictor: DR                  | Univariate Analysis | Multivariate Analysis |
|--------------------------------|---------------------|-----------------------|
|                                | OR a  | 95% CI a  | P    | OR a  | 95% CI a  | P    |
| MBL b                          | 7.12  | 3.81–13.15 | <0.0001 | 3.45  | 1.42–7.05 | <0.0001 |
| MBL(≥3rd quartiles) c          | 3.92  | 2.31–6.56  | <0.0001 | 3.10  | 1.72–5.48 | <0.0001 |
| Male sex                       | 1.20  | 1.05–1.38  | 0.005  | 1.15  | 1.06–1.28 | 0.002  |
| HbA1c                          | 1.08  | 1.03–1.20  | <0.001  | 1.05  | 1.01–1.16 | <0.001  |
| Diabetes duration              | 1.24  | 1.13–1.30  | <0.0001 | 1.16  | 1.10–1.24 | <0.0001 |
| Hs-CRP                         | 1.10  | 1.04–1.18  | <0.001  | 1.08  | 1.03–1.18 | <0.001  |
| Intensive glucosetreatment     | 2.03  | 1.25–3.45  | 0.018  | 1.90  | 0.91–3.15 | 0.311  |
| Hypertension                   | 1.58  | 1.31–1.82  | 0.009  | 1.30  | 1.12–1.44 | 0.011  |

| Predictor: VTDR                | Univariate Analysis | Multivariate Analysis |
|--------------------------------|---------------------|-----------------------|
|                                | OR a  | 95% CI a  | P    | OR a  | 95% CI a  | P    |
| MBL b                          | 9.14  | 3.16–18.22 | <0.0001 | 4.42  | 1.51–8.18 | <0.0001 |
| MBL(≥3rd quartiles) c          | 9.55  | 4.51–19.78 | <0.0001 | 7.83  | 3.35–18.31 | <0.0001 |
| Male sex                       | 1.16  | 1.06–1.46  | 0.031  | 1.08  | 1.02–1.35 | 0.037  |
| HbA1c                          | 1.12  | 1.04–1.33  | <0.001  | 1.08  | 1.03–1.16 | <0.001  |
| Diabetes duration              | 1.22  | 1.08–1.36  | <0.0001 | 1.12  | 1.04–1.25 | <0.0001 |
| Hs-CRP                         | 1.14  | 1.06–1.26  | 0.003  | 1.09  | 1.03–1.18 | 0.006  |
| Intensive glucosetreatment     | 1.22  | 1.09–1.54  | <0.001  | 1.14  | 1.06–1.28 | 0.003  |
| Hypertension                   | 1.71  | 1.27–2.30  | 0.009  | 1.58  | 1.28–2.30 | 0.006  |

aNote that the odds ratio corresponds to a unit increase in the explanatory variable.
bLog-transformed, note that the odds ratio corresponds to a log-unit increase in the explanatory variable.
cMBL(≥3rd quartiles) as one predictor in the multivariate logistic regression analysis.

DR, diabetic retinopathy; VTDR; vision-threatening diabetic retinopathy.

Fig 4. Receiver operating characteristic (ROC) curves were utilized to evaluate the accuracy of markers to diagnose DR or VTDR. (A) Receiver operator characteristic curve demonstrating sensitivity as a function of 1–specificity for diagnosing the DR based on the MBL, Hs-CRP, HbA1c and diabetes duration; (B) Receiver operator characteristic curve demonstrating sensitivity as a function of 1–specificity for diagnosing the VTDR based on the MBL, Hs-CRP, HbA1c and diabetes duration.

doi:10.1371/journal.pone.0130665.g004
was also stable in an internal 5-fold cross validation that resulted in an average AUC (standard error) of 0.85 (0.022) for the diabetes duration and 0.90 (0.014) for the combined model, corresponding to a difference of 0.05 (0.008; Table 3).

**Discussions**

Several studies have shown that deficiency of MBL increases the overall susceptibility of an individual to infectious disease [24]. The most striking example of this is the association of acute respiratory tract infections with MBL deficiency in early childhood [25]. Clinical studies have shown that MBL insufficiency is associated with bacterial infection in patients with neutropenia and meningococcal sepsis. Numerous other potential infectious disease associations have been described [26]. In contrast, there is evidence that for some intracellular parasites MBL deficiency may be protective and this might explain the high frequency of MBL mutations in sub-Saharan Africa and South America [24]. MBL is an example of a pattern recognition molecule that plays a dual role in modifying inflammatory responses to sterile and infectious injury [27].

Previous studies had suggested that there may be a link between complement activation and the development of diabetic complications [28–29]. Mounting evidence supports the importance of the MBL pathway of complement activation in innate immunity [30]. One study suggested that MBL and the lectin complement pathway play a significant role in vascular dysfunction and cardiomyopathy after acute hyperglycemia [31]. In this study, we firstly assessed the serum MBL levels with regard to their accuracy to predict DR and VTDR in patients with T2DM in Chinese sample. Consistent with our findings, Man et al. [32] also found that evaluated serum levels of MBL can be seen as an independent marker of DR even after correcting for possible confounding factors in type 2 diabetic patients.

In previous studies, Hansen et al. [21] demonstrated that circulating MBL concentrations are significantly elevated in patients with type 1 diabetes and suggested a possible role of MBL in the pathogenesis of renovascular complications in diabetes. In another study, they also found that MBL may be involved in the pathogenesis of micro- and macrovascular complications in type 1 diabetes [15]. In this study, we confirmed that elevated MBL were correlated with DR and VTDR, and added significant additional predictive information to the diabetes duration, suggesting a possible role of MBL in the pathogenesis of DR complications in T2DM.

**Table 3. Receiver operating characteristics curve analysis.**

| Parameter          | DR             | VTDR            |
|--------------------|----------------|-----------------|
|                    | AUC 95% CI P   | AUC 95% CI P    |
| MBL                | 0.84 0.80–0.89 | 0.86 0.80–0.92  |
| Age                | 0.55 0.52–0.65 | <0.0001 0.59 0.53–0.64 | <0.0001 |
| Male               | 0.57 0.54–0.64 | <0.0001 0.60 0.54–0.66 | <0.0001 |
| Diabetes duration  | 0.82 0.77–0.86 | 0.85 0.77–0.92  | 0.126 |
| Systolic blood pressure | 0.60 0.55–0.66 | 0.62 0.57–0.69 | <0.0001 |
| HbA1c              | 0.63 0.56–0.70 | <0.0001 0.69 0.60–0.78 | <0.0001 |
| Hs-CRP             | 0.58 0.52–0.65 | <0.0001 0.61 0.53–0.70 | <0.0001 |
| Combined model\*   | 0.88 0.82–0.96 | <0.01 0.90 0.83–0.96 | <0.01 |

AUC, area under the curve; CI, confidence interval; OR, odds ratio; Hs-CRP, High-sensitivity C-reactive protein; DR, diabetic retinopathy; VTDR, vision-threatening diabetic retinopathy.

\*Combined model = MBL and diabetes duration

doi:10.1371/journal.pone.0130665.t003
Similarly, Hansen et al. [33] reported that in patients with type 2 diabetes, measurements of MBL alone or in combination with CRP can provide prognostic information on mortality and the development of albuminuria.

The importance of glycaemia, blood pressure and diabetes duration as risk factors for DR is already well established [34]. Male sex has also been reported as a risk factor in other studies [35]. Importantly, in our study, we found that MBL was a risk factor for DR. In addition, male sex, diabetes duration, HbA1c, Hs-CRP and systolic BP was also reported.

High CRP and MBL levels could both be a sign of an inflammatory state, and MBL is a slower-reacting and much weaker acute-phase reactant than CRP [17]. Navarro et al [36] found that inflammatory parameters (Hs-CRP) in patients with type 2 diabetes at an early stage of nephropathy are independently associated with urinary albumin excretion (UAE). We did indeed observe significantly higher Hs-CRP levels among patients with diabetic retinopathy compared with others. However, the relationship between MBL levels and diabetic retinopathy persisted on additional adjustment for Hs-CRP, which indicates that CRP and MBL may carry different types of information as markers of inflammation.

In a meta-analysis, a total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes, and the overall prevalence was 34.6% for any DR [3]. Similarly, in our study, 35.5% of the diabetes patients had DR. Our findings are in line with reports from recent population studies in which the prevalence of DR ranged from 6% to 33% [33, 37–38]. Zhang et al. [39] reported that the estimated prevalence of DR and VDTR was 28.5% (95% confidence interval [CI], 24.9%-32.5%) and 4.4% (95% CI, 3.5%-5.7%) among US adults with diabetes, respectively. Differences in study methodologies, population characteristics, and ascertainment and classification of DR have made direct comparisons between studies difficult.

In a meta-analysis, a total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes, and the overall prevalence was 34.6% for any DR [3]. Similarly, in our study, 35.5% of the diabetes patients had DR. Our findings are in line with reports from recent population studies in which the prevalence of DR ranged from 6% to 33% [33, 37–38]. Zhang et al. [39] reported that the estimated prevalence of DR and VDTR was 28.5% (95% confidence interval [CI], 24.9%-32.5%) and 4.4% (95% CI, 3.5%-5.7%) among US adults with diabetes, respectively. Differences in study methodologies, population characteristics, and ascertainment and classification of DR have made direct comparisons between studies difficult.

Despite extensive research, the exact pathogenesis of DR is still unknown. Whether higher serum MBL level was a cause of or merely a marker for DR in diabetes remains uncertain. MBL is more likely to be a contributing factor to the DR rather than a mere marker, and may involve multiple mechanisms. Firstly, MBL is a slower-reacting and much weaker acute-phase reactant than CRP [12], but it is possible that the differences in MBL concentrations between patients with and without DR may reflect differences in inflammatory activity. In addition, MBL may aggravate local and systemic inflammation through complement activation [40] and modulation of proinflammatory cytokine production [41]. We can speculate that high levels of MBL and subsequent complement activation will result in a net proinflammatory state, potentiating allograft damage, leading downstream to chronic allograft dysfunction. It could thus be hypothesized that in diabetic patients, high levels of MBL may contribute to the development of DR through aggravated complement activation. Thirdly, oxidative stress leading to changes in cell surface glycosylations may activate the complement system via MBL [40], and MBL binding to fructoselysine and the ensuing complement activation may provide a physiopathological link between enhanced glycation and complement activation in diabetes [42]. Interestingly, we found that there was a modest positive correlation between levels of MBL and HBA1c (P<0.0001).

A number of issues have to be taken into account when interpreting the results of the present study. Firstly, without serial measurement of the circulating MBL, this study yielded no data regarding when and how long of MBL was elevated in these patients. Additionally, it should be investigated whether serial MBL testing further improves the risk stratification of these patients. Secondly, the samples were also geographically limited, potentially limiting the generalizability of our results. Larger studies are needed to confirm our results and elucidate the underlying mechanisms. Thirdly, MBL genotypes were not determined. Those results should be useful to explain the differences in MBL concentration between studies. Lastly, this was only a preliminary study; further studies should investigate whether MBL can help physicians tailor...
the therapy in view of the relative risk and allocate resources accordingly and whether this strategy might affect DR outcome.

Conclusions

The present study demonstrated that serum MBL level was an independent risk factor for DR and VDTR in Chinese patients with T2DM, suggesting a possible role of MBL in the pathogenesis of DR complications. We suggested that further studies should be carried out with respect to what was the cause of the increased MBL levels and the role in the pathology of the DR.

Acknowledgments

We express our gratitude to all the patients who participated in this study, and thereby made this work possible. Authors also acknowledge the contribution of reviewers (Velavan TP) who have helped us to improve the manuscript.

Author Contributions

Conceived and designed the experiments: QH GS YX. Performed the experiments: QH HD JL YM. Analyzed the data: QH YX. Contributed reagents/materials/analysis tools: QH GS HD JL. Wrote the paper: QH YX.

References

1. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. New England Journal of Medicine. 2010; 362: 1090–1101. doi: 10.1056/NEJMoa0908292 PMID: 20335585
2. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007; 14: 179–183. PMID: 17896294
3. Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes care. 2012; 35:556–564. doi: 10.2337/dc11-1909 PMID: 22301125
4. Liu Z, Fu C, Wang W, Xu B. Research prevalence of chronic complications of type 2 diabetes mellitus in outpatients—a cross sectional hospital based survey in urban China. Health Qual Life Outcomes. 2010; 8: 62. doi: 10.1186/1477-7525-8-62 PMID: 20579389
5. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes meta-analysis of observational studies. Diabetes Care. 2011; 34: 1238–1244. doi: 10.2337/dc11-0079 PMID: 21525504
6. Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, Cavallerano JD, et al. Diabetic retinopathy. Diabetes Care. 2003; 26:S99–S102. PMID: 12502630
7. Chang WC, White MR, Moyo P, McClell S, Thiel S, Hartshom KL, et al. Lack of the pattern recognition molecule mannose-binding lectin increases susceptibility to influenza A virus infection. BMC immunology, 2010; 11:64. doi: 10.1186/1471-2172-11-64 PMID: 21182784
8. Keller TT, van Leuven St, Meuwese MC, Wareham NJ, Luben R, Stroes ES, et al. Serum levels of mannos-binding lectin and the risk of future coronary artery disease in apparently healthy men and women. Arterioscler Thromb Vasc Biol. 2006; 26:2345–2350. PMID: 16902159
9. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunology today. 1996; 17: 532–540. PMID: 8981831
10. Bay JT, Sørensen SS, Hansen JM, Madsen HO, Garned P. Low mannose-binding lectin serum levels are associated with reduced kidney graft survival. Kidney international. 2012; 83: 264–271. doi: 10.1038/ki.2012.373 PMID: 23172101
11. Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clinical Infectious Diseases. 2003; 37: 1496–1505. PMID: 14614673
12. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Bergh G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab.2003; 88:1082–1088. PMID: 12629088
13. Özkan H, Köksal N, Cetinkaya M, Kılıç Ş, Çelebi S, Oral B, et al. Serum mannos-binding lectin (MBL) gene polymorphism and low MBL levels are associated with neonatal sepsis and pneumonia. Journal of Perinatology. 2011; 32: 210–217. doi: 10.1038/jp.2011.79 PMID: 21681178

14. Ezekowitz RA. Genetic heterogeneity of mannos-binding proteins: the Jekyll and Hyde of innate immunity? Am J Hum Genet. 1998; 62:6–9. PMID: 9443889

15. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stenhower CD, Schalkwijk CG, et al. Association between mannos-binding lectin and vascular complications in type 1 diabetes. Diabetes. 2004; 53:1570–1576. PMID: 15161763

16. Wang ZY, Sun ZR, Zhang LM. The relationship between serum mannos-binding lectin levels and acute ischemic stroke risk. Neurochem Res. 2014; 39: 248–253. doi: 10.1007/s11064-013-1214-x PMID: 24309995

17. Zhang ZG, Wang C, Wang J, Zhang Z, Yang YL, Gao L, et al. Prognostic Value of Mannose-Binding Lectin: 90-Day Outcome in Patients with Acute Ischemic Stroke. Mol Neurobiol. 2015; 51:230–239. doi: 10.1007/s12035-014-8682-0 PMID: 24691546

18. Siezenga MA, Shaw PK, Daha MR, Rabelink TJ, Berger SP. Low Mannose-Binding Lectin (MBL) genotype is associated with future cardiovascular events in type 2 diabetic South Asians. A prospective cohort study. Cardiovasc Diabetol. 2011; 10:60. doi: 10.1186/1475-2840-10-60 PMID: 21729275

19. Elawa G, AoudAllah AM, Hasaneen AE, El-Hammady AM. The predictive value of serum mannan-binding lectin levels for diabetic control and renal complications in type 2 diabetic patients. Saudi Med J. 2011; 32:784–790. PMID: 21858386

20. Bouwman LH, Earligh P, Terpstra OT, Daha MR, de Knijff P, Ballieux BE, et al. Elevated levels of mannos-binding lectin at clinical manifestation of type 1 diabetes in juveniles. Diabetes. 2005; 54: 3002–3006. PMID: 16186405

21. Hansen TK, Thiel S, Knudsen ST, Gravholt CH, Christiansen JS, Mogensen CE, et al. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J Clin Endocrinol Metab. 2003; 88: 4857–4861. PMID: 14557465

22. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs—an extension of the modified Airlie House classification: ETDRS report number 10: Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98:S786–S806.

23. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33:S62–S69. doi: 10.2337/dc10-S062 PMID: 20042775

24. Turner MW. The role of mannos-binding lectin in health and disease. Molecular Immunology. 2003; 40: 423–429. PMID: 14568388

25. Koch A, Melbye M, Serensen P, Homé P, Madsen HO, Melbak K, et al. Acute respiratory tract infections and mannos-binding lectin insufficiency during early childhood. JAMA. 2001; 285: 1316–1321. PMID: 11255386

26. Eisen DP, Minchinton RM. Impact of mannos-binding lectin on susceptibility to infectious diseases. Clinical Infectious Diseases. 2003; 37: 1496–1505. PMID: 14614673

27. Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. The Journal of Immunology. 2005; 175: 545–546. PMID: 15972690

28. Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, Angarita L, et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A 2000; 97:5450–5455. PMID: 10805801

29. Hsu SI, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors? J Am Soc Nephrol. 2003; 14:S186–S191. PMID: 12819326

30. Vang Petersen S, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: biology and disease association. Molecular immunology. 2001; 38: 133–149. PMID: 11532276

31. Pavlov VI, La Bonte LR, Baldwin WM, Markiewski MM, Lambris JD, Stahl GL. Absence of mannos-binding lectin prevents hyperglycemic cardiovascular complications. The American journal of pathology. 2012. 180: 104–112. doi: 10.1016/j.ajpath.2011.09.026 PMID: 22079428

32. Man X, Zhang H, Yu H, Ma L, Du J. Increased serum mannos-binding lectin levels are associated with diabetic retinopathy. Journal of diabetes and its complications. 2015; 29: 55–58. doi: 10.1016/j.jdiacomp.2014.09.013 PMID: 25457461

33. Hansen T K, Gall M A, Tarnow L, Thiel S, Stenhower CD, Schalkwijk CG, et al. Mannose-binding lectin and mortality in type 2 diabetes. Archives of internal medicine. 2006; 166: 2007–2013. PMID: 17030835
34. Looker HC, Nyangoma S O, Cromie D, Olson JA, Leese GP, Black M, et al. Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia. 2012; 55: 2335–2342. PMID:22688348

35. Hammes HP, Kerner W, Hofer S, Kordonouri O, Raile K, Holl RW. Diabetic retinopathy in type 1 diabetes—a contemporary analysis of 8,784 patients. Diabetologia. 2011; 54:1977–1984. doi:10.1007/s00125-011-2198-1 PMID:21638132

36. Navarro J F, Mora C, Macía M, Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. American Journal of Kidney Diseases. 2003; 42: 53–61. PMID:12830456

37. Tapp RJ, Shaw JE, Harper CA, de Courten MP, Balkau B, McCarty DJ, et al. The prevalence of and factors associated with diabetic retinopathy in the Australian population. Diabetes Care. 2003; 26:1731–1737. PMID:12766102

38. Nagi DK, Pettitt DJ, Bennett PH, Klein R, Knowler WC. Diabetic retinopathy assessed by fundus photography in Pima Indians with impaired glucose tolerance and NIDDM. Diabet Med. 1997; 14:449–456. PMID:9212309

39. Zhang X, Saaddine JB, Chou CF, Cotch MF, Saaddine J, Friedman DS. Prevalence of diabetic retinopathy in the United States, 2005–2008. JAMA. 2010; 304: 649–656. doi:10.1001/jama.2010.1111 PMID:20699456

40. Collard CD, Vakeva A, Morrissey MA, Agah A, Rollins SA, Reenstra WR, et al. Complement activation after oxidative stress: role of the lectin complement pathway. Am J Pathol. 2000; 156:1549–1556. PMID:10793066

41. Jack DL, Read RC, Tenner AJ, Frosch M, Turner MW, Klein NJ. Mannose binding lectin regulates the inflammatory response of human professional phagocytes to Neisseria meningitides serogroup B. J Infect Dis. 2001; 184:1152–1162. PMID:11598838

42. Fortpied J, Vertommen D, Van Schaftingen E. Binding of mannose-binding lectin to fructosamines: a potential link between hyperglycaemia and complement activation in diabetes. Diabetes Metab Res Rev. 2010; 26:254–260. doi:10.1002/dmrr.1079 PMID:20503257